Novel germline CDKN2A mutation associated with head and neck squamous cell carcinomas and melanomas

Head and Neck

Volumn 35, Issue 3, 2013, Pages

  Cabanillas, Rubén ^a   Astudillo, Aurora ^b   Valle, Miguel ^a   De La Rosa, Jorge ^a   Álvarez, Rebeca ^a   Durán, Noelia S ^a   Cadiñanos, Juan ^a  

^a Instituto de Medicina Oncológica y Molecular de Asturias   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

CDKN2A; genetic counseling; head and neck squamous cell carcinoma; melanoma; p16

Indexed keywords

CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ADULT; AGED; ARTICLE; AWARENESS; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CASE REPORT; CODON; DIFFERENTIAL DIAGNOSIS; FEMALE; GENE LOCUS; GENE MUTATION; HEAD AND NECK CARCINOMA; HEREDITARY ATAXIA; HUMAN; MALE; MELANOMA; OPEN READING FRAME; PEDIGREE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENES, P16; GENETIC TESTING; GERM-LINE MUTATION; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MELANOMA; MIDDLE AGED; PEDIGREE; TUMOR SUPPRESSOR PROTEINS;

EID: 84874108524     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21911     Document Type: Article

References (33)

1. Copper MP, Jovanovic A, Nauta JJ, et al. Role of genetic factors in the etiology of squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1995; 121: 157-160.
2. Werbrouck J, De Ruyck K, Duprez F, et al. Single-nucleotide polymorphisms in DNA double-strand break repair genes: association with head and neck cancer and interaction with tobacco use and alcohol consumption. Mutat Res 2008; 656: 74-81.
3. Canova C, Hashibe M, Simonato L, et al. Genetic associations of 115 polymorphisms with cancers of the upper aerodigestive tract across 10 European countries: the ARCAGE project. Cancer Res 2009; 69: 2956-2965.
4. Fletcher O, Houlston RS,. Architecture of inherited susceptibility to common cancer. Nat Rev Cancer 2010; 10: 353-361.
5. Nichols KE, Malkin D, Garber JE, Fraumeni JF, Jr., Li FP,. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev 2001; 10: 83-87.
6. German J, Sanz MM, Ciocci S, Ye TZ, Ellis NA,. Syndrome-causing mutations of the BLM gene in persons in the Bloom's Syndrome Registry. Hum Mutat 2007; 28: 743-753.
7. Kirwan M, Dokal I,. Dyskeratosis congenita: a genetic disorder of many faces. Clin Genet 2008; 73: 103-112.
8. Rosenberg PS, Socie G, Alter BP, Gluckman E,. Risk of head and neck squamous cell cancer and death in patients with Fanconi anemia who did and did not receive transplants. Blood 2005; 105: 67-73.
9. Stoepker C, Hain K, Schuster B, et al. SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype. Nat Genet 2011; 43: 138-141.
10. Yu KK, Zanation AM, Moss JR, Yarbrough WG,. Familial head and neck cancer: molecular analysis of a new clinical entity. Laryngoscope. 2002; 112: 1587-1593.
11. Vinarsky V, Fine RL, Assaad A, et al. Head and neck squamous cell carcinoma in FAMMM syndrome. Head Neck 2009; 31: 1524-1527.
12. Zhang B, Peng Z,. A minimum folding unit in the ankyrin repeat protein p16(INK4). J Mol Biol 2000; 299: 1121-1132.
13. Lilischkis R, Sarcevic B, Kennedy C, Warlters A, Sutherland RL,. Cancer-associated mis-sense and deletion mutations impair p16INK4 CDK inhibitory activity. Int J Cancer 1996; 66: 249-254.
14. Yang R, Gombart AF, Serrano M, Koeffler HP,. Mutational effects on the p16INK4a tumor suppressor protein. Cancer Res 1995; 55: 2503-2506.
15. Okami K, Reed AL, Cairns P, et al. Cyclin D1 amplification is independent of p16 inactivation in head and neck squamous cell carcinoma. Oncogene 1999; 18: 3541-3545.
16. Lynch HT, Fusaro RM, Lynch JF, Brand R,. Pancreatic cancer and the FAMMM syndrome. Fam Cancer 2008; 7: 103-112.
17. Rizos H, Puig S, Badenas C, et al. A melanoma-associated germline mutation in exon 1beta inactivates p14ARF. Oncogene 2001; 20: 5543-5547.
18. Laud K, Marian C, Avril MF, et al. Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma. J Med Genet 2006; 43: 39-47.
19. Lesueur F, de Lichy M, Barrois M, et al. The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma. Br J Cancer 2008; 99: 364-370.
20. Whelan AJ, Bartsch D, Goodfellow PJ,. Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med 1995; 333: 975-977.
21. Kluijt I, Cats A, Fockens P, Nio Y, Gouma DJ, Bruno MJ,. Atypical familial presentation of FAMMM syndrome with a high incidence of pancreatic cancer: case finding of asymptomatic individuals by EUS surveillance. J Clin Gastroenterol 2009; 43: 853-857.
22. Schneider-Stock R, Giers A, Motsch C, et al. Hereditary p16-Leiden mutation in a patient with multiple head and neck tumors. Am J Hum Genet 2003; 72: 216-218.
23. Yarbrough WG, Aprelikova O, Pei H, Olshan AF, Liu ET,. Familial tumor syndrome associated with a germline nonfunctional p16INK4a allele. J Natl Cancer Inst 1996; 88: 1489-1491.
24. Della Torre G, Pasini B, Frigerio S, et al. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation. Br J Cancer 2001; 85: 836-844.
25. Sun S, Pollock PM, Liu L, et al. CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein. Int J Cancer 1997; 73: 531-536.
26. Oldenburg RA, de Vos tot Nederveen Cappel WH, van Puijenbroek M, et al. Extending the p16-Leiden tumour spectrum by respiratory tract tumours. J Med Genet 2004; 41: e31.
27. Goldstein AM, Stacey SN, Olafsson JH, et al. CDKN2A mutations and melanoma risk in the Icelandic population. J Med Genet 2008; 45: 284-289.
28. Bishop DT, Demenais F, Goldstein AM, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 2002; 94: 894-903.
29. Begg CB, Orlow I, Hummer AJ, et al. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst 2005; 97: 1507-1515.
30. Borg A, Sandberg T, Nilsson K, et al. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 2000; 92: 1260-1266.
31. Orlow I, Begg CB, Cotignola J, et al. CDKN2A germline mutations in individuals with cutaneous malignant melanoma. J Invest Dermatol 2007; 127: 1234-1243.
32. Kannengiesser C, Brookes S, del Arroyo AG, et al. Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients. Hum Mutat 2009; 30: 564-574.
33. Goldstein AM, Struewing JP, Fraser MC, Smith MW, Tucker MA,. Prospective risk of cancer in CDKN2A germline mutation carriers. J Med Genet 2004; 41: 421-424.